Get 25% discount on our yearly plans! Subscribe now

Key Metrics
Market Cap
Total Shares Outstanding
Book Value
PE Ratio
PS Ratio
PB Ratio
Forward PE Ratio
ROIC
Return on Aseets
Return on Equity
Dividend
Dividend Yield
Balancesheet Metrics
Total Assets 8.47M
Total Liability 13.95M
Assets-to-Libability Ratio 0.61
Total Current Assets 8.47M
Total Current Liability 4.80M
Current Ratio 1.76
Quick Ratio -
Debt to Equity Ratio -
Income Statement Metrics
Net Income
EPS
EBITA
Gross Profit
Gross Profit Margin
Operating Margin
Net Profit Margin
Price Metrics
5 Days MA
10 Days MA
20 Days MA
50 Days MA
200 Days MA
52 Weeks High
52 Weeks low
All Time High
RSI
MACD
Share Stats
Shares Float
Shares Short
% Short
% Insider
% Institutions
News
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination AgreementSEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (PBAX), a special purpose acquisition company spon...

PBAX | globenewswire | about 3 years ago | Neutral
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis DisordersIntrinsic’s pipeline consists of drug candidates based on human milk oligosaccharides (HMOs), which are bioactive small molecules that naturally occur in human milk, with the potential to transform the treatment of Gut-Brain Axis and inflammatory disorders through multiple mechanisms of action, incl...

PBAX | globenewswire | about 3 years ago | Neutral
Phoenix Biotech Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on November 26, 2021Oakland, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that the holders of the Company’s units may elect to separately trade t...

PBAX PBAXU PBAXW | globenewswire | about 4 years ago | Neutral
Phoenix Biotech Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment OptionOakland, CA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) (the “Company”), a blank-check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more bu...

PBAX PBAXU PBAXW | globenewswire | about 4 years ago | Neutral
Phoenix Biotech Acquisition Corp. Announces Pricing of $155,000,000 Initial Public OfferingOakland, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) (the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more bu...

PBAX PBAXU PBAXW | globenewswire | about 4 years ago | Neutral

Profile

Phoenix Biotech Acquisition Corp (PBAX)

Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe. Phoenix Biotech Acquisition Corp. was incorporated in 2021 and is based in Oakland, California.

Exchange: NASDAQ

IPO Date: 11/30/2021

Sector: Financial Services

Industry: Shell Companies

Employees: 0

Address: 2201 Broadway, Oakland, CA, United States, 94612

https://www.phoenixbiotechacquisitioncorp.com